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Abstract Cytochalasin B is a potentially novel microfilament-
directed chemotherapeutic agent that prevents actin polymeriza-
tion, thereby inhibiting cytokinesis. Although cytochalasin B has
been extensively studied in vitro, only limited data are available
to assess its in vivo potential. Cytochalasin Bwas administered to
Balb/cmice challenged i.d. withM109murine lung carcinoma to
determine whether the agent could affect an established i.d.
tumor when the compound is administered s.c. in the region of
the i.d. tumor, but not in direct contact with it. Cytochalasin B
was also administered either i.p. or s.c. at a distant site or i.v. to
determine whether it could affect the long-term development of
an established i.d. tumor. Cytochalasin B was then liposome
encapsulated to determine whether the maximum tolerated dose
(MTD) of the compound could be increased, while reducing
immunosuppression that we have previously characterized. Li-
posomal cytochalasin B was also administered to mice chal-
lenged i.d. with M109 lung carcinoma to assess its chemothera-
peutic efficacy. The results can be summarized as follows: 1)
cytochalasin B substantially delayed the growth of i.d. M109
tumor nodules, inhibited metastatic progression in surrounding
tissues, and produced long-term cures in treated mice; 2) liposo-
mal cytochalasin B increased the i.p. MTD by more than 3-fold,
produced a different distribution in tissue concentrations, and
displayed antitumor effects againstM109 lung carcinoma similar
to non-encapsulated cytochalasin B. These data show that cyto-
chalasin B exploits unique chemotherapeutic mechanisms and is
an effective antineoplastic agent in vivo in pre-clinical models,
either in bolus form or after liposome encapsulation.
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Introduction
Cytochalasins are mycogenic toxins known to disrupt the
formation of actin polymers, thereby preventing the formation
of functional microfilaments. These congeners are character-
ized by a highly substituted perhydro-isoindolone structure
that is typically attached to a macrocyclic ring [1]. More than
60 different cytochalasins from several species of fungi have
been classified into various subgroups based on the size
of the macrocyclic ring and the substituent of the
perhydroisoindolyl-1-one residue at the C-3 position [2].
However, the most studied congener in regards to antineo-
plastic activity has been cytochalasin B. As a microfilament-
disrupting agent, cytochalasin B alters cell motility, adher-
ence, secretion, drug efflux, deformability, morphology, and
size, among many other effects [1, 2]. The effects of cytocha-
lasin B on cell adherence include alteration of cell junctions,
leading to changes in tissue physiology and transport.
Perhaps the best characterized cellular property of cytocha-
lasin B is its ability to prevent formation of the contractile ring,
as well as development of the cleavage furrow, thereby
inhibiting cytokinesis [3, 4]. While normal proliferating cells
enter the G0 resting state until sufficient actin levels have been
gathered for successful cytokinesis, malignant cells typically
continue to progress through the cell cycle, resulting in the
formation of enlarged, multinucleated cells. The
multinucleation phenomenon is almost exclusively observed
in neoplastic cells, potentially representing a neoplastic-
targeting feature of cytochalasin B, as well as other congeners
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[5–12]. This apparent partial specificity of cytochalasin action
on neoplastic cells is consistent with a separate body of
evidence showing substantial differences in microfilament
biochemistry between neoplastic and comparable non-
neoplastic cells [13]. These differences in microfilament struc-
tures may be related to key neoplastic characteristics, includ-
ing altered adherence, anchorage independent growth, inva-
siveness, and altered plasma membrane cytoskeletal interac-
tions involving expression of oncoproteins [14].
These observations lead us to propose that cytochalasin B
might affect experimental cancer chemotherapy model systems
in vivo, either as single agents, or as agents amplifying re-
sponses of known chemotherapeutic agents. Mechanisms of
action of microtubule-directed or of nucleic acid-directed
agents might be affected by microfilament dependent phenom-
ena (see Ref 4 for detailed explanations of potential drug
synergy). We propose that the cytochalasins as microfilament-
directed agents may enhance the antineoplastic activity of other
cytoskeletal-directed agents such as the microtubule-disrupting
vinca alkaloids, or the microtubule-stabilizing taxanes.
In previous work, we developed procedures for the prepara-
tion of cytochalasins in quantities sufficient to support compre-
hensive in vivo evaluation, and we have defined the conditions
for the formulation, administration, and limiting doses for in-
traperitoneal (i.p), intravenous (i.v)., and subcutaneous (s.c.)
treatment [15, 16], as well as the kinetics of tissue distribution
to 14 tissues after i.p. treatment [15]. We have established that
cytochalasin B administered s.c. in mice peritumorally to s.c.
challenges of B16F10 murine melanoma, or of M109 murine
lung carcinoma is able to inhibit invasion and spontaneous lung
metastases, and in the case of both models to increase life span
[16]. Further, our in vitro and in vivo analyses of B16F10 cells
suggest that the antitumor effects of localized cytochalasin B do
not arise from gross toxicitiy, but rather may depend on other
features of host-tumor interaction.
However, the immunosuppressive effects of cytochalasin B
in vivo raise concern. While cytochalasin B has demonstrated
substantial antitumor activity, the maximum tolerated dose
(MTD) is limited due to immunosuppression observed in the
spleen, coupled with marked splenomegaly [15, 16]. We have
demonstrated that this immunosuppression can be reversed
through the introduction of human recombinant interleukin-2
(rhIL-2) [17], but developing a safer vehicle by which to
transport cytochalasin B to malignant cells is pivotal for its
development as a chemotherapeutic agent. Liposomes have
been extensively examined for their abilities to improve drug
delivery, and have been used for a substantial variety of
medicines, including cytotoxic agents, antibiotics and antifun-
gal agents [18]. In regards to cancer therapy, liposome encap-
sulation has been shown to reduce side effects of a variety of
chemotherapeutic agents, as well as promote targeted tumor
damage due in part to their ability to substantially aggregate at
tumor sites by leaking through pores and defects in tumor
capillary endothelium [18]. In fact, cytochalasin D, a congener
of cytochalasin B that has a toxicity in mice that is 20-fold
higher than does cytochalasin B [19], has demonstrated re-
duced toxicity, as well as increased efficacy after being en-
capsulated in polyethylene glycol (PEG) coated liposomes
[20]. It may be possible to dramatically increase the MTD of
cytochalasin B, while reducing its immunosuppressive effects
through liposome encapsulation.
Therefore, this study seeks to determine the following: 1)
whether cytochalasin B in vivo can affect an established
intradermal (i.d.) tumor when the compound is administered
s.c. in the region of the i.d. tumor, but not in direct contact with
it; 2) whether cytochalasin B administered either i.p. or s.c. at
a distant site can affect the long-term development of an
established i.d. tumor; 3) whether cytochalasin B systemically
administered i.v. can affect the subsequent development of a
localized, potentially invasive and spontaneously metastatic
i.d. tumor; 4) whether the MTD of cytochalasin B in mice can
be elevated through liposome encapsulation; and 5) whether
the tissue distribution and anticancer activity of liposomal
cytochalasin B is similar to that of the non-encapsulated
compound.
Materials and Methods
Conversion of M109 to Continuous Culture (M109c)
M109 murine lung carcinoma cells were converted to contin-
uous culture using methods previously described [21]. As in
the previous paper of this series [21], comparison between
animals challenged i.d. with M109c cells and matched groups
challenged with in vivo passaged M109 cells showed that the
challenges were indistinguishable in terms of growth kinetics,
invasion, metastasis, and host survival.
M109 Lung Carcinoma In Vivo
M109 murine lung carcinoma was maintained as a spontaneous-
ly invasive and metastatic model by serial passage s.c. in Balb/c
mice as previously detailed [4, 22], except that the passage
challenge was 2×105 trypan blue negative cells. Prolonged
tumor passage i.d. afforded a gradually less invasive and meta-
static variant that permitted longer term measurements of a
completely localized primary i.d. nodule. When this subline
was used, the tumor challenge is designated M109ni.
For chemotherapy testing, Balb/c mice under isoflurane
anesthesia (Sigma-Aldrich Corp., St. Louis, MO, USA) were
challenged i.d. on the lower right ventral quadrant over the
peritoneum after first removing hair with a chemical depilato-
ry agent. The challenge dose was 2×105 trypan blue negative
cells in a volume of 200 μl. Tumor cells were obtained from
early s.c. tumor in vivo passaged donors (M109), from
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prolonged i.d. passaged donors (M109ni), or from continuous
cultures of M109 lung carcinoma cells (M109c). Tumor
growth was monitored by daily caliper measurements, which
were facilitated by the localized growth of the i.d. challenge
contained entirely in a region initially free of hair. Whereas
invasion took place with the M109 or M109c nodules, local-
ized tumor growth tended to become variable after about
14 days, when invasion accompanied by systemic metastatic
spread had occurred. Non-invasive and non-metastatic
M109ni cells permitted the monitoring of primary tumor
growth until reaching a limiting predetermined tumor size
(18 mm in any one direction) or until host conditions dictated
termination. Therefore, survival in the M109 and M109c
challenged groups is based on systemic tumor effects, whereas
survival in the M109ni challenged groups is an extension of
primary tumor measurements. Effects on primary tumor
appearance, growth rate, invasion, and metastases to the lungs,
liver, kidneys, pancreas and spleen were determined as previous-
ly detailed for s.c. challenges with M109 tumor [16].
Cytochalasin B Preparation, Bolus Formation
and Administration
Cytochalasin B was prepared frommold mattes ofDrechslera
dematioidea (ATCC 24346) as previously described, and
purified by preparative thin layer chromatography to greater
than 99 % homogeneity after recrystallization from chloro-
form. The compound was prepared in suspension form in 2 %
carboxymethyl cellulose 1 % tween 20 for s.c. administration,
and in solution in 33 % ethanol: 0.9 % NaCl solution for i.v.
use as previously described [15, 16].
Liposomal Cytochalasin B Preparation
Liposomal cytochalasin B was prepared by suspending 2.0 mg
cytochalasin B in 2.0 ml chloroform containing 200 mg of egg
phosphatidylcholine (Sigma-Aldrich Corp.). The solution was
pipetted into a round bottom flask and dried to a thin film. The
film was then resuspended in 5 ml phosphate buffered saline
(Sigma-AldrichCorp). The resulting suspensionwas left to sit for
1 h before being extruded five times through a 5.0 μm polycar-
bonate filter in accordance to LUVET (large unilamellar vesicles
made by an extrusion technique), forming large, unilamellar
vesicles. The above mentioned protocol was then repeated using
200 mg total of a 70:30 mixture of egg phosphatidylcholine:
dimyristoylphosphatidylglycerol.
Determining the Extent of Reduction in Immunosuppression
Potentiated by Liposomal Cytochalasin B
To determine whether liposomal cytochalasin B had less of an
immunosuppressive effect than its natural counterpart, dose–
response and time-course study of the influence that i.p. bolus
injection had on spleen response to an allogeneic sensitizer
and target tumor cell in vitro were performed as previously
described [17]. Splenic lymphocytes frommice were removed
following natural or liposomal cytochalasin B treatment and
exposed to X-radiated P815 murine mastocytoma tumor anti-
gen as described in [23] with the modifications presented in
[24]. As in [17], the cytotoxic activity of sensitized spleen
cells was determined in a standard 4 h Cr-release assay. Spleen
cell number after sensitization and washing was checked by
triplicate hemacytometer counts to confirm the final effector:
target (E:T) ratios to permit comparisons among the treatment
groups at equivalent ratios. The percentage of 51Cr release was
determined through the formula 51Cr release=[(51Cr superna-
tant/(51Cr pellet+51Cr supernatant)]×100. The percentage of
specific Cr release represents values obtained with immune
effectors minus values obtained from control lymphocytes
cultured for 4 days in the absence of P815 antigen. Control
lymphocytes were prepared from each of the groups treated at
various cytochalasin B or liposomal cytochalasin B concen-
trations, or with the vehicle.
Statistics
Survival analysis used the Cox-Mantel test as detailed by Lee
[25]. Effects on tumor growth rates were evaluated by Repeat-
edMeasures Analysis of Variance using SAS software. Test of
hypotheses for between subject effects were applied, and of
time vs. group interactions using the Geisser-Greenhouse
adjustment in cases where tests of orthogonal components
showed absence of sphericity. Differences in lung metastases
between treated and control groups were evaluated with a
Student-Fisher t-test.
Results
Conversion of In Vivo Passaged M109 Cells to Continuous
Culture (M109c) Cells
M109c cells seeded at 4×104 cells/cm2 grew as attached cells
and reached confluency at 2×105 cells/cm2 after 5 days. The
attached cells were compared to the in vivo passaged cells for
tumorigenicity defined as fraction of animals developing tu-
mor and time to appearance of palpable tumor nodules,
growth rate, invasion, and formation of spontaneous metasta-
ses. Growth curves in vivo for i.d. tumors produced by chal-
lenge with 2×105 M109c cells were fully superimposable for
19 days with growth curves obtained in mice challenged with
4×105 M109c trypan blue negative in vivo passaged M109
cells. After 21 days, spontaneous lung metastases had a mean
value of 80.3 nodules per mouse (SEM=19.7) for tumors
produced by the attached cells, compared to a mean of 86.6
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nodules per mouse (SEM=13.6) for tumors produced from
in vivo passaged cells. Neither of the tumor sources produced
significant numbers of metastases to the liver, kidney, spleen,
or pancreas. Tumors grew and invaded in all animals chal-
lenged i.d. with either tumor source.
Effects of S.C. Cytochalasin B Bolus Suspension
on Established I.D. M109 and M109c Tumors
Cytochalasin B administered s.c. as a single bolus dose at
100 mg/kg (Fig. 1a), or three such doses spaced at two-day
intervals (Fig. 1b) peritumorally to nascent day 1 challenges
(Fig. 1a) or to established i.d. (0.5 mm diameter) nodules
(Fig. 1b) of M109 tumor, significantly inhibited the rate of
tumor growth in treated animals. Multiple dose treatments
produced growth inhibitory effects statistically more signifi-
cant than single dose treatments. Multiple dose treatment
increased median survival by 33% in treated animals (15 days
in controls, compared to 20 days in the treated group, signif-
icant at the 0.05 level by U-test. The mean number of metas-
tases to the lungs at the respective terminal stages was not
significantly affected.
Treatment of established i.d. tumor nodules of M109c on
days 6, 8, and 10 after tumor implantation with bolus cyto-
chalasin B under conditions identical to those used in Fig. 1b
produced significant inhibition of tumor growth rate
(P<0.001 between subject effects; p, 0.01 time vs. group
interaction by repeated measures analysis of variance) (data
not shown). Spontaneous lung metastases determined on day
17 showed a mean number of lung nodules in controls of 23.5
nodules per mouse (SEM=9.7) compared to 8.3 nodules per
mouse (SEM=4.1) in the treated group (n=10). This inhibi-
tion of spontaneous lung metastases formation was significant
at the P<0.05 level.
Effects of I.V. (Systemic) Cytochalasin B on I.D. Challenge
with M109c Tumor Cells
Animals challenged withM109c cells i.d. (day 0) were treated
daily with i.v. cytochalasin B solution in ethanol-saline at
5 mg/kg/day for 4 or 5 successive days beginning 1 day after
tumor implantation. Figure 2a shows a strong systemic effect
on tumor growth rate produced by i.v. cytochalasin B. It is
apparent from Fig. 2a that the growth inhibition is not signif-
icant until after day 15, 10 days after the final i.v. drug
treatment. The potential implications of this observation will
be addressed in the discussion.
As detailed in Fig. 2a, animals treated with i.v. cytochalasin
B showed a marked increase in survival duration, and 4 out of
10 animals were tumor-free on day 53 (Fig. 2b). This effect is
significant at the 0.03 level by a Cox-Mantel test. Lung
metastases at the terminal stages measured in vehicle controls
showed a mean value of 73.7 nodules per mouse (SEM=9.4)
compared to a value of 22.7 nodules per mouse (SEM=3.7), a
70 % reduction, for the six treated animals that succumbed to
the tumor challenge (P<0.05).When all 10 treated animals are
used in the determination of “terminal” lung metastases, in-
cluding the 4 long-term tumor-free survivors, the mean be-
comes 13.6 nodules per mouse (SEM=4.3) an 82% reduction
compared to the vehicle controls.
Effects of I.P. and of Distal S.C. (Non-Peritumoral)
Cytochalasin B on Established I.D. Tumor Nodules
Mice were challenged with M109ni cells i.d., and then strat-
ified into two treatment and one control groups, 10 animals
Fig. 1 Mean volume of M109 lung carcinoma intradermal nodules
treated with subcutaneously administered cytochalasin B. Balb/c mice
were administered s.c. cytochalasin B (CB) 100 mg/kg/day in 2 % CM-
cellulose/1 % Tween 20 after challenge with 2×105 M109 cells on day 0.
Control indicates mice treated only with the vehicle in which CB was
administered. CC=cm3. a Single dose treatment with CB day 1. There
were 16 mice per group, with half being sacrificed on day 8, the
remainder being sacrificed on day 16; p<0.01 for between subject
effects, and p<0.08 for time vs. group interaction. b Multiple dose
treatment of established tumor nodule with CB days 7, 9, and 11. There
were 10 mice per group; p<0.05 for between subject effects, and p<0.01
for time vs. group interaction. Bars reflect standard error of the mean
(SEM) of the treatment groups
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per group, according to tumor size on day 3. Treatments were
given on days 4, 7, 10, and 13; 50 mg/kg/day i.p., or
1 00 mg / kg / d a y s . c . , w i t h c y t o c h a l a s i n B i n
carboxymethylcellulose-tween suspension as detailed in the
materials and methods section. The i.d. tumor challenge was
in the lower left anterior quadrant over the peritoneal cavity.
Cytochalasin B treated i.p. or s.c. was monitored to day 35.
Figure 3 shows the results obtained. Marked systemic activity
is apparent as tumor growth inhibition with both i.p. and non-
peritumoral s.c. treatment. Statistical analysis of the separate
i.p or s.c. treated groups compared to controls to day 24
showed marginal significance (between subject effects
p<0.07 and p<0.09 respectively). Combined i.p. and s.c.
treated groups compared to controls to day 24 was statistically
significant (between subject effects p<0.05).
Efficacy of Encapsulating Cytochalasin B in Liposomes
As previously shown [17] 50 mg/kg cytochalasin B adminis-
tered i.p. inmice produced amarked inhibition in the allogenic
response to a P815 antigen. By contrast, liposomal cytocha-
lasin B was well tolerated in mice at 150 mg/kg i.p (Fig. 4).
Although immunosuppression was noticeable with 150mg/kg
cytochalasin B, it was not as dramatic as the natural compound
at only 50 mg/kg. In addition, liposomal cytochalasin B
demonstrated marked differences in tissue distribution, as
assessed by Balb/c mice (Fig. 5a) in comparison with tissue
distribution of non-encapsulated cytochalasin B (Fig. 5b).
Liposomal cytochalasin B sustained a high concentration in
the mesentery and pancreas, while non-encapsulated cytocha-
lasin B localized in the liver. The time of distribution for
liposomal cytochalasin B was also markedly different from
non-encapsulated cytochalasin B. Liposomal cytochalasin B
wasmeasurable for more than 2 weeks inmesentery, pancreas,
and spleen, whereas non-encapsulated cytochalasin B was
cleared from four out of six tissues examined within 2 days.
Non-encapsulated cytochalasin B was measurable at only
very low levels in the liver and mesentery after 2 days.
One hundred eighty milligram/kilogram liposomal cyto-
chalasin B s.c. had considerable in vivo anticancer activity
against M109 lung carcinoma. There was a 66.7 % survival
rate at least up to day 62 for mice challenged with two i.d.
tumor nodules in the cohort treated with liposomal cytochala-
sin B on day 8 (Fig. 6a). This is a highly significant prolonging
of life expectancy, as all controls were dead by day 36. In
Fig. 2 Intravenously administered cytochalasin B against M109 murine
lung carcinoma. a Effect of intravenously administered cytochalasin B on
growth of intradermal M109 carcinoma nodules. 10mice received at least
4 injections of CB at 5 mg/kg in 33% ethanol:0.9 %NaCl solution i.v. on
days 1–5 following challenge on day 0 with 2×105 M109c cells i.d. 16
Balb/c mice received vehicle i.v. as a control. CC=cm3. The CB-treated
group was significantly different from the controls; p<0.02 for between
subject effects, p<0.05 for time vs. group interactions. Bars reflect SEM
of the treatment groups. b Effects of intravenously administered
cytochalasin B on survival of Balb/c mice. Both treated and control
micewere administered the same concentrations of cytochalasin B or vehicle-
only as shown in Fig. 2a. Survival of treated mice (n=10) was significantly
different from controls (n=16); p<0.05, as assessed by a Cox-Mantel test
Fig. 3 Effects of cytochalasin B administered intraperitoneally or non-
peritumoral subcutaneously on long-term growth of established M109ni
tumor nodules. Cytochalasin B was administered at 50 mg/kg/day for i.p.
treatments, and 100 mg/kg/day for s.c. treatments on days 4, 7, 10 and 13.
CC=cm3. There were 10 mice per treatment group; i.p. treated group
p<0.07, s.c. treated group p<0.09. Combined i.p. and s.c. treated groups
p<0.04 for between subject effects
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addition, the same dose of liposomal cytochalasin B markedly
reduced the extent of lung metastases observed in Balb/c mice
18 days after challenge of a single i.d. tumor nodule (Fig. 6b).
It is unclear whether this ability would hold true in other
tissues, as the challenge did not produce significant metastases
in the liver, pancreas, or spleen. A particularly intriguing
finding was that 90 mg/kg liposomal cytochalasin B admin-
istered twice i.p. on days 8 and 13 to tumor-bearing mice
with a single i.d. nodule was able to preclude further tumor
growth and produce actual tumor shrinkage after the second
injection (Fig. 7). A single treatment with liposomal cyto-
chalasin B at 90 mg/kg on day 8 inhibited tumor growth
compared to empty liposomal controls, but the tumor con-
tinued to grow.
Discussion
The novel and pleotypic effects of cytochalasins on cells and
tissues in vitro have prompted us to predict that these agents
will exhibit measurable antitumor activity in vivo by mecha-
nisms which do not depend extensively on gross toxicity [16].
Further, the peculiar properties of cytochalasins suggest that
they may be as effective as, or even more effective against
solid tumor masses than against free cell neoplasms, because
the cell and tissue features affected by cytochalasins are likely
to be more important in organized tumor tissue. The relatively
low host toxicity exhibited by cytochalasins B is favorable for
obtaining significant in vivo preclinical activity against neo-
plastic growths. Antineoplastic activity is supported by this
study, by our previous studies [16, 21], and in the early
experience of others in the use of cytochalasins in vivo [26,
27].
Cytochalasin B administered peritumorally in the same
compartment [16], locally in separate compartments, or sys-
temically i.p., s.c., or i.v. is active against established tumor
nodules, whereas it is inactive when administered i.p. against
early i.p. challenges with ascites cancers [16]. This suggests
there are some effects on developing solid tumors that may not
be as important or as effective at earlier free-cell stages
immediately after tumor suspension implantation. It is also
evident from Fig. 2a, that i.d. tumor growth inhibition pro-
duced by i.v. administration of cytochalasin B does not be-
come significant until after day 15, 10 days after the final i.v.
treatment. This delayed effect appears long after drug clear-
ance, and suggests an indirect mechanism relating to host
response, or to tissue architecture in developing tumor nodules
that may not necessarily rely on immediate acute cytotoxicity.
In our previous study [16], we observed that cytochalasin B
administered i.p. was ineffective as a bolus drug suspension in
mice challenged i.p. with suspensions of M109 lung carcino-
ma, or of B16F10 melanoma. By contrast, s.c. challenges of
either tumor model exhibited marked sensitivity to
peritumoral treatment with s.c. cytochalasin B. In the case of
s.c. B16F10 tumor treated with s.c. cytochalasin B, analysis of
tumor cell viability, clonogenicity, and tumorigenicity, after
drug treatment in vivo demonstrated no evidence of measur-
able cytotoxicity in tumors whose growth was markedly
inhibited [16]. These observations are consistent with a mech-
anism of antitumor activity for cytochalasin B that is not
dependent on gross toxicity.
Fig. 4 Time course of effect of
cytochalasin B/liposomal
cytochalasin B on allogeneic
response in vitro for E:T of 50:1.
Cytochalasin B (CB) or liposomal
cytochalasin B (CB Lpsm) was
injected i.p. into mice. Spleen
lymphocytes were then recovered
and sensitized to X-radiated P815
murine tumor antigen for 4 days.
The cytotoxic activity of
sensitized spleen lymphocytes
was determined in a standard 4 h
Cr-release assay, and then
compared to control lymphocytes
from untreated mice or those
treated with the vehicle, which
was shown not to have an
immunosuppressive effect
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The s.c. peritumoral activity of cytochalasin B against s.c.
nodules of M109 lung carcinoma has now been extended to
established i.d. nodules of M109 tumor where the agent is
administered s.c. peritumorally, and to models where direct
contact between s.c. cytochalasin B and the i.d. tumor nodule
does not occur (Fig. 1a and b). Cytochalasin B administered in
a multiple dose protocol either s.c. at a site distant from an
established i.d. tumor nodule, or i.p. against an established i.d.
tumor is also able to substantially inhibit tumor growth
(Fig. 3). These results indicate that direct drug-tumor contact
is not needed in order for cytochalasin B to achieve a chemo-
therapeutic response, thereby demonstrating systemic antitu-
mor activity.
Systemic antitumor activity elicited by cytochalasin B
against nascent M109 i.d. tumor nodules is confirmed in
Fig. 2 which show that cytochalasin B administered i.v. to
mice challenged i.d. with M109 tumor cells inhibits tumor
growth rate and formation of spontaneous lung metastases, as
well as extends host survival with a 40% (4/10) cure rate. This
again demonstrates that direct contact between the adminis-
tered drug and tumor challenge is not required to produce
antitumor activity. The fact that low levels of cytochalasin B
administered i.v. (20–25 mg/kg over a 4–5 day period) is
active against M109 lung carcinoma, and that the compound
does not exhibit activity until 10 days after final i.v. treatment
(Fig. 2a), argues against a direct cytotoxic effect. This further
supports the postulation that cytochalasin B has an indirect
effect on tumor growth, or affects host response that inhibits
tumor growth by a delayed mechanism.
Although the anticancer activity of cytochalasin B is sub-
stantial, it may be beneficial to encapsulate the agent in
liposomes before it is administered in vivo. A three-fold
increase in the i.p. MTD compared with non-encapsulated
cytochalasin B was achieved by the liposomal derivative, with
less immunosuppression being observed at this elevated dose
(Fig. 4). In addition, liposomal cytochalasin B appears to have
Fig. 5 Comparison of tissue
distribution for liposomal and
natural cytochalasin B. a
150 mg/kg liposomal
cytochalasin B (CB Lpsm) i.p. in
Balb/c mice. b 50 mg/kg Natural
cytochalasin B (CB) i.p. in Balb/c
mice. Analyses were performed
by analytical high performance
liquid chromatography (HPLC)
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a much longer time of tissue distribution, as well as a different
tissue distribution compared to non-encapsulated cytochalasin
B (Fig. 5). Liposomal cytochalasin B also demonstrated
marked anticancer activity against M109 lung carcinoma, as
assessed by a prolonging in life expectancy, and a substantial
reduction in lung metastases (Fig. 6). These in vivo effects on
metastastic reduction are very similar to the in vivo anti-
metastatic effects of non-encapsulated cytochalasin B (dem-
onstrated in this study [4, 16]). The reduced immunosuppres-
sion by liposomal cytochalasin B with retention of anti-
metastatic properties suggests that the liposomal formulation
may be superior to non-encapsulated cytochalasin B for
treatment of metastasizing or metastatic neoplasms. It was
also shown that two 90 mg/kg i.p. injections, separated 5 days
apart, can mitigate further tumor growth of i.d. nodules and
can produce tumor shrinkage (Fig. 7).
This study demonstrates that cytochalasin B produces both
localized, separate compartment, and systemic antitumor ac-
tivity against established tumor nodules. The activity is evi-
denced by significant alterations to tumor growth rate, inva-
sion, metastases, host survival time, and in some cases, com-
plete tumor regression. Direct gross toxicity is unlikely to be
responsible for the effects observed, although toxic effects on
sensitive clonogenic subpopulations of tumor cells are not
excluded by these data. The localized and systemic perturba-
tions of solid tumors, and the long-delayed influence observed
with i.v. drug treatment suggest that direct toxicity is not the
sole, or even the most important mechanism by which cyto-
chalasin B exerts in vivo activity. Therefore, it appears plau-
sible that the effects of cytochalasin B in vivo depend on
features of tumor tissue physiology, as well as the host re-
sponse to solid tumors. In addition, liposomal cytochalasin B
Fig. 6 In vivo activity of
liposomal cytochalasin B against
M109 lung carcinoma. a
Longitudinal analysis of tumor-
bearing mice (peritumoral and
distal) survival after treatment with
180 mg/kg CB Lpsm s.c. 8 days
after tumor challenge. Size of each
treatment group is indicated in the
figure. b A separate cohort of
tumor-bearing mice (peritumoral)
were treated with 180 mg/kg CB
Lpsm s.c. 8 days after tumor
challenge to determine whether CB
Lpsm could reduce the number of
metastases found in vehicle-only
treated and untreated mice 18 days
after tumor challenge. NT not
treated. Size of all treatment groups
are indicated in the figure. Bars
reflect SEM of treatment group
Invest New Drugs (2015) 33:280–289 287
appears to be an attractive formulation of the agent, exhibiting
decreased host toxicity and increased efficacy with favorable
effects on host immune response. The liposomal formulation
of cytochalasin B and of other cytochalasin congeners may
increase the opportunity to develop microfilament-directed
agents that are of value in the clinical management of
neoplasms.
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